Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Basal cell nevus syndrome: a brave new world.
Goldberg LH, Firoz BF, Weiss GJ, Blaydorn L, Jameson G, Von Hoff DD. Goldberg LH, et al. Among authors: jameson g. Arch Dermatol. 2010 Jan;146(1):17-9. doi: 10.1001/archdermatol.2009.322. Arch Dermatol. 2010. PMID: 20083687 No abstract available.
Blackberry-induced hand-foot skin reaction to sunitinib.
Boone SL, Jameson G, Von Hoff D, Lacouture ME. Boone SL, et al. Among authors: jameson g. Invest New Drugs. 2009 Aug;27(4):389-90. doi: 10.1007/s10637-008-9196-2. Epub 2008 Nov 8. Invest New Drugs. 2009. PMID: 18998055
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.
Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, Fitch TR, Wasserman E, Fernandez C, Green S, Sutherland W, Bittner M, Alarcon A, Mallery D, Penny R. Von Hoff DD, et al. Among authors: jameson g. J Clin Oncol. 2010 Nov 20;28(33):4877-83. doi: 10.1200/JCO.2009.26.5983. Epub 2010 Oct 4. J Clin Oncol. 2010. PMID: 20921468
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.
Weiss GJ, Hidalgo M, Borad MJ, Laheru D, Tibes R, Ramanathan RK, Blaydorn L, Jameson G, Jimeno A, Isaacs JD, Scaburri A, Pacciarini MA, Fiorentini F, Ciomei M, Von Hoff DD. Weiss GJ, et al. Among authors: jameson g. Invest New Drugs. 2012 Dec;30(6):2334-43. doi: 10.1007/s10637-011-9774-6. Epub 2011 Dec 9. Invest New Drugs. 2012. PMID: 22160853 Free PMC article. Clinical Trial.
Determinants of patient screen failures in Phase 1 clinical trials.
Mckane A, Sima C, Ramanathan RK, Jameson G, Mast C, White E, Fleck S, Downhour M, Von Hoff DD, Weiss GJ. Mckane A, et al. Among authors: jameson g. Invest New Drugs. 2013 Jun;31(3):774-9. doi: 10.1007/s10637-012-9894-7. Epub 2012 Nov 8. Invest New Drugs. 2013. PMID: 23135779
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
Jameson GS, Hamm JT, Weiss GJ, Alemany C, Anthony S, Basche M, Ramanathan RK, Borad MJ, Tibes R, Cohn A, Hinshaw I, Jotte R, Rosen LS, Hoch U, Eldon MA, Medve R, Schroeder K, White E, Von Hoff DD. Jameson GS, et al. Clin Cancer Res. 2013 Jan 1;19(1):268-78. doi: 10.1158/1078-0432.CCR-12-1201. Epub 2012 Nov 7. Clin Cancer Res. 2013. PMID: 23136196 Free PMC article. Clinical Trial.
A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer.
Jameson GS, Petricoin EF, Sachdev J, Liotta LA, Loesch DM, Anthony SP, Chadha MK, Wulfkuhle JD, Gallagher RI, Reeder KA, Pierobon M, Fulk MR, Cantafio NA, Dunetz B, Mikrut WD, Von Hoff DD, Robert NJ. Jameson GS, et al. Breast Cancer Res Treat. 2014 Oct;147(3):579-88. doi: 10.1007/s10549-014-3117-1. Epub 2014 Sep 11. Breast Cancer Res Treat. 2014. PMID: 25209003 Clinical Trial.
291 results